Methotrexate is a prescription-only medication used in Hong Kong for both autoimmune disorders and certain cancers. It belongs to the therapeutic categories of Autoimmune Support and Oncology Support. The medication is available as a pill (tablet) containing 2.5 mg of the active ingredient methotrexate. In Hong Kong, methotrexate is regulated under the Pharmacy and Poisons Ordinance and may be dispensed only with a qualified healthcare-provider’s prescription.
Methotrexate is a folate antagonist. It blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into tetrahydrofolate-a co-factor required for the synthesis of purines and thymidylate. By limiting these building blocks, methotrexate interferes with DNA, RNA, and protein synthesis, a mechanism that is especially effective against rapidly dividing cancer cells.
At lower weekly doses used for autoimmune conditions, methotrexate also increases extracellular adenosine levels. Adenosine acts as an anti-inflammatory mediator, dampening the activity of immune cells such as T-lymphocytes and neutrophils. This dual action-antiproliferative and anti-inflammatory-explains methotrexate’s efficacy in both oncology and immune-mediated diseases.
These indications are approved by the Hong Kong Department of Health and reflect the drug’s dual role in modulating the immune system and inhibiting malignant cell growth.
Research has investigated methotrexate for several conditions that are not formally approved in Hong Kong:
Because these uses are off-label, they require careful clinical judgment and close monitoring. Off-label use must be overseen by a qualified healthcare provider and patients should be informed of the experimental nature of the therapy.
These effects are usually dose-related and may diminish with folic acid supplementation (commonly 1 mg daily, taken on non-methotrexate days).
Any signs of severe toxicity warrant immediate medical evaluation.
If patients are uncertain about any medication, supplement, or herbal product, they should disclose all items to their prescribing clinician.
Baseline labs before initiation:
Complete blood count (CBC) with differential.
Liver function tests (ALT, AST, bilirubin).
Serum creatinine and calculated creatinine clearance.
Pregnancy test for women of child-bearing potential.
Routine monitoring:
CBC and liver enzymes every 4-8 weeks for the first three months, then every 8-12 weeks thereafter.
Renal function every 8-12 weeks.
Pulmonary assessment (history, physical exam, chest X-ray if indicated) at baseline and periodically.
Clinical follow-up: Patients should report new respiratory symptoms, persistent fatigue, unexplained bruising, or signs of infection promptly.
This article provides educational information about methotrexate and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Methotrexate tablets are permitted in both carry-on and checked luggage. It is advisable to keep the medication in its original pharmacy-labelled container, carry a copy of the prescription, and have a brief physician letter if you are traveling internationally, as some countries require documentation for controlled medications.
Routine workplace drug screens (e.g., urine immunoassays for cannabinoids, opiates, cocaine) do not detect methotrexate. However, targeted testing for chemotherapeutic agents can identify it, and certain sports anti-doping programs may consider it a prohibited substance if used without a therapeutic use exemption.
The 2.5 mg tablets are typically round, white or off-white, and may bear a numeric imprint such as “2.5” or a manufacturer’s logo. Verify the imprint, shape, and packaging against the pharmacy label each time you receive a refill.
Weekly dosing allows sufficient drug exposure to achieve anti-inflammatory effects while minimizing cumulative toxicity, especially bone-marrow suppression. Daily dosing would lead to higher steady-state levels and a markedly increased risk of severe adverse events.
Concurrent NSAIDs can reduce renal clearance of methotrexate, potentially raising blood levels and toxicity risk. Short-term, low-dose NSAID use is sometimes permitted under close monitoring, but patients should discuss any NSAID use with their prescriber before combining the drugs.
Alcohol is metabolised by the liver and can synergistically increase the risk of methotrexate-induced hepatotoxicity. Limiting or avoiding alcohol while on methotrexate is recommended, especially for patients with existing liver enzyme elevations.
Methotrexate is excreted in breast milk and can cause fetal toxicity. Health authorities advise against breastfeeding during treatment and for at least three months after the last dose to avoid infant exposure.
Injectable methotrexate (intramuscular or subcutaneous) bypasses gastrointestinal absorption, leading to more predictable serum concentrations, especially at higher doses. Oral forms are convenient for low-dose weekly regimens but may have variable bioavailability in some patients.
Clinical improvement often begins within 4-6 weeks of initiating low-dose weekly methotrexate, but maximal benefit may require 3-6 months of steady therapy and dose optimisation. Ongoing monitoring helps assess response and guide adjustments.
Reduced renal clearance can lead to higher systemic methotrexate levels, increasing the risk of bone-marrow and mucosal toxicity. Dose reduction, extended dosing intervals, or choosing an alternative therapy may be necessary for patients with moderate to severe renal impairment.
